Therapeutic blocking of the CCL2/CCR2 axis counteracts the tumor-induced immunosuppression and leads to the activation of a CD8+ T cell anti-tumor response, attributed to the inhibition of MoMF infiltration and TAM polarization. This evidence concerns the gene CD8A and neoplasm.